Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market Business Wire (Press Release) 21:17 Mon, 03 Aug
Dr Reddy’s gets US FDA approval for cancer biosimilar Rituximab, enters US market The Financial Express 06:07 Mon, 03 Aug
SMC uncovers 'decoy' mechanism behind rituximab resistance in lymphoma Korea Biomedical Review 03:26 Thu, 23 Jul
Long-Term RELEVANCE Data Reinforce Lenalidomide Plus Rituximab as Frontline Chemo-Free Option for FL Hematology Advisor 15:51 Mon, 20 Jul
Celltrion and Teva’s TRUXIMA® Becomes First Interchangeable Rituximab Biosimilar in U.S. JD Supra 17:14 Fri, 10 Jul
Rituximab Preserves Kidney Function Yet Exposes FSGS Risk in Pediatric SRNS Rare Disease Advisor 20:07 Thu, 09 Jul
Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx) - July 2026 JD Supra 17:46 Thu, 09 Jul
EHA: Adding Pirtobrutinib to Venetoclax-Rituximab Ups PFS in Chronic Lymphocytic Leukemia Hematology Advisor 14:28 Wed, 08 Jul
Rituximab Anti-Drug Antibodies Emerge Early in FSGS but May Not Affect Efficacy Renal and Urology News 14:27 Wed, 08 Jul
Genmab Announces Tepkinly® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma Business Wire (Press Release) 18:55 Mon, 06 Jul
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma AbbVie (Press Release) 18:45 Mon, 06 Jul
